WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will release its second-quarter 2025 financial results on Thursday, August 14. The company will also host a live investor call at 8:30 a.m. ET the same day to discuss earnings and provide a corporate update.
The webcast, which will include presentation slides, will be accessible through the company’s website. A replay will be available within two hours of the call and remain archived for 90 days.
Palvella, a clinical-stage biopharma firm, focuses on developing treatments for rare genetic skin diseases with no FDA-approved options. Its lead candidate, QTORIN™ 3.9% rapamycin gel, is currently in late-stage trials for two vascular skin disorders.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.